Symbol
| STMN2
| contributors: mct/shn - updated : 06-12-2022
|
HGNC name
| stathmin-like 2
|
HGNC id
| 10577
|
Other morbid association(s)
|
Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
---|
constitutional
|  
|  
| --low
|  
|
is found in neurons trans-differentiated from patient fibroblasts expressing an ALS-causing TARDBP mutation, in motor cortex and spinal motor neurons from patients with sporadic ALS | |
Susceptibility
|
to Alzheimer disease to sporadic ALS (sALS) |
Variant & Polymorphism
other
| non-coding CA repeat in Stathmin-2 which is associated with sporadic ALS (sALS) disease risk and has disease modifying effects |
|
truncated STMN2 is a marker for TARDBP dysfunction in frontotemporal dementia (FTD) |
|
|
Candidate gene
Marker
| utility of STMN2 as an efficient and selective marker of sensory axon regeneration | Therapy target
|
System | Type | Disorder | Pubmed |
cancer | digestive | stomach | |
blocking PAK4-mediated STMN2 phosphorylation might be a potential therapeutic strategy for metastasis of gastric cancer | neurology | neurodegenerative | | |
restoring STMN2 expression warrants examination as a therapeutic strategy for amyotrophic lateral sclerosis (ALS) |
| | |
| Both mosaic founders and homozygous loss-of-function Stmn2 mice exhibited neuromuscular junction denervation and fragmentation, resulting in muscle atrophy and impaired motor behavior, accompanied by an imbalance in neuronal microtubule dynamics in the spinal cord | |
STMN2 knockout heterozygous mice, which better model the partial loss of STMN2 protein found in patients with ALS, display a slowly progressive, motor-selective neuropathy with functional deficits and neuromuscular junction (NMJ) denervation |